<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121820</url>
  </required_header>
  <id_info>
    <org_study_id>BIOMEM-20</org_study_id>
    <nct_id>NCT03121820</nct_id>
  </id_info>
  <brief_title>Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects</brief_title>
  <official_title>A Two-way Crossover, Open-label, Single-dose, Fasting, Bioequivalence Study of Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) 20 mg Tablets Versus Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany) 20 mg Tablets in Normal Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study are two-way crossover, open-label, single-dose, fasting, bioequivalence study of
      Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) 20 mg tablets versus Akatinol Memantine® (Merz Pharma
      GmbH &amp; Co. KGaA, Germany) 20 mg tablets in normal healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to evaluate the bioequivalence of orally administered memantinol preparations,
      film-coated tablets, 20 mg
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2016</start_date>
  <completion_date type="Actual">November 19, 2016</completion_date>
  <primary_completion_date type="Actual">November 19, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>two-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of memantinol by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))</measure>
    <time_frame>0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of memantinol sourced in Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) and Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of memantinol by Assessment of Observed Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0 hours (pre-dose), as well as at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of memantinol sourced in Memantinol® (JSC &quot;GEROPHARM&quot;, Russia) and Akatinol Memantine® (Merz Pharma GmbH &amp; Co. KGaA, Germany)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Bioequivalence, AUC, Cmax, Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Memantinol tablets, 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC &quot;GEROPHARM&quot;, Russia - test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Akatinol Memantine® tablets, 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH &amp; Co. KGaA, Germany - reference)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantinol tablets, 20 mg</intervention_name>
    <description>Bioequivalence Memantine Hydrochloride (JSC &quot;GEROPHARM&quot;, Russia) 20 mg film-coated tablets fasting condition</description>
    <arm_group_label>Memantinol tablets, 20 mg</arm_group_label>
    <other_name>memantine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Akatinol Memantine® tablets, 20 mg</intervention_name>
    <description>Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH &amp; Co. KGaA, Germany) 20 mg film-coated tablets fasting condition</description>
    <arm_group_label>Akatinol Memantine® tablets, 20 mg</arm_group_label>
    <other_name>memantine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form.

          -  Healthy male and female subjects aged 18 to 45 years.

          -  Verified diagnosis is &quot;healthy&quot; according to data Standard clinical, laboratory and
             Instrumental methods of examination.

          -  Have a body mass index between 18,5 and 27 kg/m2.

          -  Females must have a negative pregnancy test.

          -  Subjects must use, with their partner, methods of highly effective contraception; if
             the Hormonal contraceptives was used they must canceled have at least 2 month before
             the study.

        from the time of IMP administration until 3 months after the last dose of IMP.

        Exclusion Criteria:

          -  History of serious allergic problems/events

          -  Medicinal intolerance.

          -  History of allergic reactions to memantine or investigator's product components

          -  Any acute and chronic diseases of the cardiovascular system, cardiovascular,
             bronchopulmonary, neuroendocrinal systems, as well as diseases of the gastrointestinal
             tract, liver, kidneys, blood.

          -  Acute infectious diseases in less than 4 weeks before the start of the study.

          -  Subjects who have taken medication 4 weeks preceding before the study.

          -  Subjects who have taken any drugs known effects on hemodynamics or to induce or
             inhibit hepatic drug metabolism within 30 days prior to administration of the study
             medication (examples of inducers: barbiturates, omeprazole, etc.).

          -  Donation of plasma (450 mL or more) within 2 month prior to administration of the
             study medication.

          -  History of significant alcohol or drugs abuse or any indication of the regular use of
             more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or
             50 mL of alcohol 40%).

          -  Smokers.

          -  Participation in other clinical training is less than than for 3 months before the
             study.

          -  Lack of signed informed consent form.

          -  ECG or vital signs abnormalities (clinically significant).

          -  Positive testing for alcohol, drugs, pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 20, 2017</submitted>
    <returned>December 15, 2017</returned>
    <submitted>February 13, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

